InMode - Pioneer in Aesthetics

My opinions on DOMA’s list

  1. Agree with point 1. Currently, for example, the CEO himself leads the US team. One would think that if this continues for too long, it would hinder both the CEO’s work and the operations of the US team. However, we are talking about the most important market. A new leader should be found for this position without delay.

  2. Perhaps disagree with point 2. However, the products are reasonably high-level technology and there is skilled personnel in Israel. In my opinion, it’s a big plus that product development and manufacturing are in the same place.

Points 3, 5, 6 sound good. Utilize the cash because no business operations with equally good margins have been found for acquisition.
4. No thanks to dividends.

3 Likes

Bringing the decentralization of production capacity outside of Israel would indeed be a healthy development from a risk management perspective, especially since the region tends to be perhaps a bit more unstable. A new production facility would, however, be “just” a replication of equipment and processes; employees would certainly learn how to operate them – just guessing off the top of my head :slight_smile:

I don’t know anything about product development – where or how they do it – but they could continue on the same path with that, as it has worked quite well so far.

Well, as for dividends, it’s almost all the same to me whether they are distributed or not. It could, however, grow the ownership base when the criteria of dividend believers are met :man_shrugging:

1 Like

Unbelievable, I no longer wonder about the company’s capital allocation…

https://x.com/wolfofharcourt/status/1882714843649909193?t=at59iLjqrAUxuBheyMJ0hQ&s=19

Screenshot_20250124_110609_X

8 Likes

Wow, absolutely unbelievable writing. I seriously have to consider leaving this outfit.

3 Likes

The CEO’s statement is strange, and if I recall correctly, it was already questioned 2 years ago. This statement was, if I recall correctly, given in early 2023. Since then, a share buyback has been made, and there would be capacity for significantly larger ones. And there is no information about the CEO’s current opinion; hopefully, it has changed in a more buyback-favorable direction.

5 Likes

Yes, quite incredible commentary from Moshel back then, fortunately, after these, the gentleman has been replaced from the HPJ (Hallituksen Puheenjohtaja - Chairman of the Board) position.

Q2 24 conference call:
“On your second question, we did a buyback of 8.37 million shares, which is exactly 10% of the total outstanding shares that we had.

Why is it 10%? Because of some tax issues. If we do more than 10%, we’ll have to pay, according to the Israeli IRS, we’ll have to pay dividend tax. They allow us to do, and hopefully they will allow us to continue but we ask for a pre-ruling from the Israeli IRS, and they allow us to do 8.37 million shares, which is about 10% of the total shares. And if we will decide in the future to continue with buyback, all the options are on the table right now.”

Moshel personally seems to enjoy investing at these prices, 01/16/2025:

“The Reporting Person acquired 1,524,196 Shares of the Issuer covered by this Schedule 13D, in multiple open market transactions for an aggregate purchase price of approximately US $23,858,317

The same announcement revealed that at the end of 2024, the number of shares would have been 69,558,570 pcs.

At the end of 2023, the number of shares was 83,982,462 pcs.

So, last year, roughly ~14.4 million pcs, or ~17.2% of its own shares, were bought.

Now, it’s time for a new and larger program.

If nothing else, at least we are moving in the right direction.

“During 2021, the Company purchased 693,734 shares in the amount of $35.4 million. In addition, during 2022, the Company purchased 1,077,213 shares in the amount of $42.6 million. During 2023 the company did not purchase any shares. As of December 31, 2023, the Company purchased 2,557,829 shares in the amount of $95.2 million under these repurchase programs”

8 Likes

Results out. Weak numbers as expected, found here: InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

Full Year 2024 Highlights:

  • Full year revenues of $394.8 million, a year-over-year decrease of 20%.
  • Full year revenues from consumables and service of $79.3 million, a decrease of 1% compared to 2023.
  • Returned $285.4 million of capital to shareholders in full year 2024

As of December 31, 2024, InMode had cash and cash equivalents, marketable securities and short-term bank deposits of $596.5 million.

Continuation of share repurchases:
On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months. Together with our 2024 share repurchases, this represents approximately 27% of share capital to be bought within less than 15 months.

And:
we are also exploring, in consultation with financial, legal and tax advisors, returning significant additional capital by the end of the year to create further shareholder value.

If we could just get back on the growth path, I’m sure this will turn out quite well.

5 Likes

Inmode CEO Moshe Mizhary has responded with an open letter to DOMA’s previous claims and demands, e.g., regarding capital returns and shareholder value creation, etc.

In the letter, he goes through all the points of the demands in detail. In my opinion, it’s a good and factual response. Of course, public feedback has certainly enabled all the recent positive news related to capital utilization.

Regarding the question: Address crucial business risks by moving a significant portion of production outside Israel."…

This answer, from the perspective of a product development engineer, pleased my ears.

Screenshot_2025-03-06-21-03-09-35_40deb401b9ffe8e1df2f1cc5ba480b12

3 Likes

InMode: Insane Margins, Explosive Growth, and Ridiculously Cheap – The Stock You Can’t Afford to Miss

A LinkedIn article about InMode by an Indian guy unknown to me.

My main interest was that it comprehensively covered other companies and competitors in the same field, such as Cynosure.

2 Likes

1 Like

Q1/ 2025

Screenshot_2025-04-28-16-19-55-95_40deb401b9ffe8e1df2f1cc5ba480b12

-Record turnover in Europe

-More difficult in the United States

-27% of shares purchased for 412 million dollars in 12 months.

-Cash position 512.9 million dollars

Screenshot_2025-04-28-16-12-21-54_40deb401b9ffe8e1df2f1cc5ba480b12

2 Likes




7 Likes
1 Like

The increasing prevalence of GLP-1 weight loss drugs and skin changes caused by weight loss may bring additional demand for Inmode’s devices and beauty treatments

1 Like

I’m not holding my breath waiting for demand to grow, as weight loss drugs have already been available for people who can afford them for a few years now. Let’s hope for the best.

I’d like to try inMode’s devices myself. I can’t exactly poke myself with a liposuction device, though; I wish there was a plastic surgeon who could say if inMode’s gadgets differ in any way from those of competitors.

1 Like

Inmode already released preliminary Q2 results on July 10.

  • Revenue for the second quarter of 2025 to be in the range of $95.4 million to $95.5 million
  • Non-GAAP1 gross margin for the second quarter of 2025 to be in the range of 79% to 80%
  • Full year 2025 revenue to be in the range of $365 million to $375 million, compared to prior guidance of $395 million to $405 million

As stated in the Q1 earnings call, if Q2/2025 revenue does not exceed $100 million, the full-year guidance would have to be lowered.

This is what happened, and the guidance was lowered once again. Q2 should be the second best quarter of the year, historically accounting for approximately 25-27 percent of total revenue. I will wait for the Q2 earnings call and its insights. The turnaround does not seem to be happening this year yet.

3 Likes

https://seekingalpha.com/article/4806343-inmode-ltd-inmd-q2-2025-earnings-call-transcript

Q2 tulos ja tulospuhelun teksti.

Q2 tulos tiedettiin jo ennalta ja Tällä kertaa ei tulospuhelun annissakaan ei mitään kovin uutta ja ihmeellistä.

Gurufocuksesta nopeasti kopioituna pääkohdat.

Positive Points

  • InMode Ltd reported strong revenue growth, reaching $95.6 million in Q2 2025, up from $86.4 million in Q2 2024.
  • The company maintained a robust gross margin of 80% on a GAAP basis, consistent with the previous year.
  • Sales outside the US increased by 11% year-over-year, with Europe contributing a record $23 million in revenue.
  • InMode Ltd (INMD) is expanding its global footprint with new direct operations in Thailand and Argentina, enhancing local presence and customer support.
  • The company is launching new platforms in the wellness space, targeting increased blood circulation and pain relief, with a full commercial rollout expected in Q4 2025.

Negative Points

  • InMode Ltd (INMD) faced challenges in the North American medical aesthetic market due to reduced personal spending, impacting capital investments from physicians.
  • The company adjusted its 2025 revenue guidance downward to $365 million to $375 million, from the previous $395 million to $405 million, due to ongoing market challenges.
  • Sales and marketing expenses increased year-over-year, reflecting higher salaries and travel costs, impacting overall profitability.
  • The company experienced a slight decline in non-GAAP gross margins, dropping from 81% in Q2 2024 to 80% in Q2 2025.
  • InMode Ltd (INMD) noted that the US market is facing stronger headwinds compared to Europe and Asia, affecting overall sales performance
2 Likes

Doma has again sent an open letter to Inmode’s management.

They demand the continuation of share buybacks such that
10% of the cash would be used for purchases in Q4/2025 and another 10% in Q1/2026.

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

3 Likes

Has the head of Inmode’s US operations been chosen? They have been with Inmode for a few years already.

1 Like

Based on preliminary results, management expects:

  • Revenue for the third quarter of 2025 to be in the range of $92.5 million to $93.0 million

  • Non-GAAP1 gross margin for the third quarter of 2025 to be in the range of 77% to 79%

  • Full year 2025 revenue to be in the range of $365 to $375 million, consistent with prior guidance